Home hover Guidelines hover Expert hover Compare hover Faq hover Submit hover About hover Resources hover Syntheses hover Myngc hover Guidelinematrix hover
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC
< Back

'combination drug therapy'
Run an advanced search on this term

Search within:  

Sort results by:      



Filter results by:

1-20 of 564   Next >
 
1.  
Dapagliflozin in combination therapy for treating type 2 diabetes. 2013 Jun. NGC:009946
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
2.  
Empagliflozin in combination therapy for treating type 2 diabetes. 2015 Mar. NGC:010695
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
3.  
Recommendations for drug therapies for relapsing-remitting multiple sclerosis. 2013 Oct. NGC:010418
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization. View all guidelines by the developer(s)
4.  
Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. 2012 Feb. NGC:009078
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
7.  
HIV drug - drug interactions. 2004 (revised 2010 Apr). NGC:007756
New York State Department of Health - State/Local Government Agency [U.S.]. View all guidelines by the developer(s)
8.  
9.  
Drug allergy: an updated practice parameter. 2010 Oct. NGC:009335
American Academy of Allergy, Asthma and Immunology - Medical Specialty Society; American College of Allergy, Asthma and Immunology - Medical Specialty Society; Joint Council of Allergy, Asthma and Immunology - Medical Specialty Society. View all guidelines by the developer(s)
10.  
Interagency guideline on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid therapy. 2007 Mar (revised 2010 Jun). NGC:007902
Washington State Agency Medical Directors' Group - Independent Expert Panel. View all guidelines by the developer(s)
11.  
12.  
Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. 2005 Jan (reaffirmed 2010 Oct 30). NGC:004046
American College of Allergy, Asthma and Immunology - Medical Specialty Society; American College of Chest Physicians - Medical Specialty Society. View all guidelines by the developer(s)
14.  
Optimal use recommendations for second- and third-line therapy for patients with type 2 diabetes. 2010 Aug (revised 2013 Jul). NGC:009997
Canadian Agency for Drugs and Technologies in Health - Nonprofit Organization. View all guidelines by the developer(s)
16.  
17.  
Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. 2008 (revised 2011). NGC:008788
World Health Organization - International Agency. View all guidelines by the developer(s)
18.  
19.  
New antiretroviral drugs: maraviroc, raltegravir, etravirine, and rilpivirine. 2008 Apr (revised 2011 Nov). NGC:008821
New York State Department of Health - State/Local Government Agency [U.S.]. View all guidelines by the developer(s)
1-20 of 564   Next >